Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics director Jean Jacques Bienaime bought 2,000 shares of common stock in an open-market transaction. The purchase took place on March 9, 2026 at a weighted average price of $11.21 per share, with individual trade prices ranging from $10.98 to $11.48. Following this transaction, Bienaime directly owns 7,450 Keros shares. The filing notes that the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the purchase was scheduled in advance rather than timed discretionarily.
Keros Therapeutics filed an 8-K describing new clinical steps for its lead drug candidate, rinvatercept. The company has entered into an agreement with Massachusetts General Hospital to design a Phase 2 trial of rinvatercept in amyotrophic lateral sclerosis within the biomarker-driven Healey ALS MyMatch program.
Keros also reported presenting additional data from a Phase 1 trial of rinvatercept in healthy volunteers. Rinvatercept was generally well tolerated and produced changes in body composition, including increased muscle mass, reduced fat mass and higher bone mineral density, along with proteomic evidence of target engagement and effects on fibrosis, inflammation and energy metabolism.
The company highlighted preclinical mouse data in Duchenne muscular dystrophy and ALS models, and reiterated plans to advance rinvatercept into two Phase 2 clinical trials, one in Duchenne muscular dystrophy and one in ALS.
Keros Therapeutics filed an 8-K describing new clinical steps for its lead drug candidate, rinvatercept. The company has entered into an agreement with Massachusetts General Hospital to design a Phase 2 trial of rinvatercept in amyotrophic lateral sclerosis within the biomarker-driven Healey ALS MyMatch program.
Keros also reported presenting additional data from a Phase 1 trial of rinvatercept in healthy volunteers. Rinvatercept was generally well tolerated and produced changes in body composition, including increased muscle mass, reduced fat mass and higher bone mineral density, along with proteomic evidence of target engagement and effects on fibrosis, inflammation and energy metabolism.
The company highlighted preclinical mouse data in Duchenne muscular dystrophy and ALS models, and reiterated plans to advance rinvatercept into two Phase 2 clinical trials, one in Duchenne muscular dystrophy and one in ALS.
Keros Therapeutics furnished an updated corporate presentation outlining its pipeline and a major partnership for elritercept. The company highlights rinvatercept (KER-065), a TGF-β ligand trap in Phase 2 planning for Duchenne muscular dystrophy, with additional plans to engage regulators on a Phase 2 trial in amyotrophic lateral sclerosis in the second half of 2026.
The deck also details elritercept (KER-050), licensed globally (excluding mainland China, Hong Kong and Macau) to Takeda. Keros received a $200 million upfront payment and is eligible for over $1.1 billion in development, approval and commercial milestones, plus tiered royalties from low double-digits to high teens. A global Phase 3 RENEW trial in lower-risk myelodysplastic syndromes is underway, with transfusion independence as the primary endpoint.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing protein therapeutics that modulate TGF-ß signaling to treat neuromuscular and hematologic disorders. Its lead neuromuscular candidate, rinvatercept (KER-065), targets myostatin and activin A to increase muscle and bone mass and reduce fat and fibrosis.
The company plans a Phase 2 trial of rinvatercept in Duchenne muscular dystrophy in the second quarter of 2026 and intends to engage regulators on a Phase 2 trial in amyotrophic lateral sclerosis in the second half of 2026. A completed Phase 1 trial in healthy adults showed no serious adverse events and signals of increased lean mass, improved bone markers and reduced fat mass.
Its most advanced asset, elritercept (KER-050), is designed to correct ineffective hematopoiesis and treat cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. A global placebo-controlled Phase 3 RENEW trial in transfusion-dependent lower-risk MDS is under way. In December 2024, Keros signed an exclusive license with Takeda for elritercept outside mainland China, Hong Kong and Macau, receiving a $200 million upfront payment and a $10 million Phase 3 milestone, plus potential development, commercial and sales milestones and tiered royalties.
Keros Therapeutics reported a strong turnaround in 2025, moving to net income of $87.0 million from a net loss of $187.4 million in 2024. Total 2025 revenue rose to $244.1 million, driven largely by license revenue from its agreement with Takeda. Research and development expenses fell to $129.6 million as Takeda assumed elritercept-related costs, while general and administrative expenses increased modestly to $46.8 million. Keros ended 2025 with $287.4 million in cash and cash equivalents and expects this to fund operations into the first half of 2028. The company is advancing rinvatercept into a Phase 2 trial in Duchenne muscular dystrophy and planning Phase 2 trial design discussions for amyotrophic lateral sclerosis in 2026.
Keros Therapeutics reported that Chief Executive Officer Jasbir Seehra received grants of employee stock options covering a total of 317,000 shares of common stock. One grant for 217,000 options vests over time, with one-fourth vesting on February 24, 2027 and the remainder in twelve equal quarterly installments thereafter, contingent on continued service.
The second grant for 100,000 options vests in four equal tranches based on stock price performance. Each one-fourth vests if the company’s share price closes at or above 125%, 150%, 175% and 200% of the exercise price, respectively, for 30 calendar days between February 24, 2026 and February 24, 2031, subject to Seehra’s continuous service. These are option awards, not open-market stock purchases or sales.
Regnante Keith reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics reported that its Chief Financial Officer, Keith Regnante, received a grant of stock options covering 60,000 shares of common stock. These options were awarded as an employee stock option grant at a stated price per share of $0.0000.
According to the terms, one-fourth of the options will vest on February 24, 2027, and the remaining options will vest in twelve substantially equal quarterly installments after that date, as long as he continues to provide service through each vesting date. After this award, he holds 60,000 derivative securities directly.
Cho Esther reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics Chief Legal Officer Esther Cho reported an equity award of employee stock options. On February 24, 2026, she was granted 80,000 options to buy Keros Therapeutics common stock, all held as direct ownership, bringing her total derivative holdings to 80,000 options.
According to the vesting terms, one-fourth of the shares subject to the option will vest on February 24, 2027. The remaining shares will then vest in twelve substantially equal quarterly installments, as long as she continues to provide service through each vesting date.
Lerner Lorena Raquel reported acquisition or exercise transactions in this Form 4 filing.
Keros Therapeutics Chief Scientific Officer Lorena Raquel Lerner received a grant of 75,000 employee stock options on February 24, 2026. These options were awarded at no cost as part of her compensation and increase her directly held derivative securities to 75,000.
One-fourth of the option grant will vest on February 24, 2027, with the remaining options vesting in twelve substantially equal quarterly installments after that date, so long as she continues to provide services to the company through each vesting date.
Keros Therapeutics, Inc. appointed Charles Newton to its Board of Directors as a Class III director, effective March 9, 2026, with his term expiring at the 2026 annual meeting of stockholders. He will also serve on the Compensation and Audit Committees.
Newton will receive the company’s standard non-employee director compensation, including an initial stock option grant and an initial restricted stock unit award, each with a grant date fair value of $150,000, plus ongoing annual equity awards with grant date fair values of $75,000 each. He will also receive annual cash retainers totaling $57,000 for his Board and committee service and will enter into Keros’ standard indemnification agreement.
Carl Gordon, Ph.D., CFA, notified the Board of his resignation, effective March 9, 2026. The company states his resignation is not due to any disagreement regarding its operations, policies or practices. Keros concurrently updated the composition of its Audit, Compensation and Nominating and Corporate Governance Committees.